



Katten Client Mylan Wins Patent Infringement Case Regarding Parkinson's Drug Treatment

June 11, 2021

In the case of *UCB, Inc. et al. v. Mylan Technologies Inc.*, partner and co-chair of the Intellectual Property Department Deepro Mukerjee and Intellectual Property partners Lance Soderstrom and Jitty Malik successfully represented Vermont-based Mylan Technologies Inc., after the global generic and specialty pharmaceutical company was sued by UCB Inc., a global biopharmaceutical company claiming that Mylan infringed on UCB's patent of its Neupro drug to treat Parkinson's disease. In June, US District Judge Christina Reiss in Delaware issued a final judgement that ruled in Mylan's favor, invalidating UCB's patent of the drug, avoiding a bench trial that was scheduled for mid-July.

Judge Reiss' final decision comes after Third Circuit Judge Kent A. Jordan had invalidated one of two patents asserted against Mylan in April, which UCB has said it will appeal to the Federal Circuit. Both Mylan and UCB agreed to adopt Judge Jordan's final judgement as it relates to one of the patents. For the second patent, both parties agreed to dismiss the infringement and validity claims.

[Parkinson's Drug Patent Ax In Del. Helps Mylan Win In Vt.](#)

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Deepro R. Mukerjee

+1.212.940.8552

deepro.mukerjee@katten.com



Lance A. Soderstrom

+1.212.940.6330

lance.soderstrom@katten.com



Jitty Malik, PhD

+1.704.344.3185

jitty.malik@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2025 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.